Stock SGHT SIGHT SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Real-time Estimate Cboe BZX
Other stock markets
 11:18:53 2024-06-12 am EDT 		5-day change 1st Jan Change
7.08 USD +5.83% Intraday chart for Sight Sciences, Inc. -1.40% +36.63%
May. 28 Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis MT
May. 28 Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sight Sciences Announces the Release of its First Sustainability Report
AQ
Sight Sciences Announces Publication of a New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI across Mild, Moderate, and Advanced Glaucoma
AQ
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
AQ
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
AQ
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
AQ
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
AQ
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
AQ
Sight Sciences : SGHT Proxy - Apr'24
PU
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
AQ
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
GL
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
AQ
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
AQ
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
AQ
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
AQ
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting
AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
AQ
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
AQ
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
AQ
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGHT Stock
  4. News Sight Sciences, Inc.
  5. Press Releases